General Information of the Drug (ID: M6APDG00616)
Name
CCS1477
Synonyms
CCS-1477; CBP-IN-1; 2222941-37-7; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one; SCHEMBL20094038; SCHEMBL21515367; SCHEMBL22134021; EX-A3687; NSC818619; NSC-818619; HY-111784; CS-0091862; (S)-1-(3,4-Difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one
    Click to Show/Hide
Status
Phase 1/2
Structure
Formula
C30H32F2N4O3
InChI
1S/C30H32F2N4O3/c1-17-29(18(2)39-34-17)19-7-14-26-25(15-19)33-30(36(26)20-8-11-22(38-3)12-9-20)27-5-4-6-28(37)35(27)21-10-13-23(31)24(32)16-21/h7,10,13-16,20,22,27H,4-6,8-9,11-12H2,1-3H3/t20?,22?,27-/m0/s1
InChIKey
SKDNDJWEBPQKCS-RIQBOWGZSA-N
PubChem CID
134457551
TTD Drug ID
DIY4C2
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
CREB-binding protein (CREBBP)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
Response Summary CREB-binding protein (CREBBP) is a therapeutic target for CCS1477. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CCS1477 through regulating the expression of CREB-binding protein (CREBBP). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
Response Summary CREB-binding protein (CREBBP) is a therapeutic target for CCS1477. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of CCS1477 through regulating the expression of CREB-binding protein (CREBBP). [2], [3]
References
Ref 1 N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell. 2015 Jun 4;161(6):1388-99. doi: 10.1016/j.cell.2015.05.014.
Ref 2 BET inhibitors in cancer therapeutics: a patent review. Expert Opin Ther Pat. 2016;26(4):505-22. doi: 10.1517/13543776.2016.1159299. Epub 2016 Mar 15.
Ref 3 N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014 Jan 2;505(7481):117-20. doi: 10.1038/nature12730. Epub 2013 Nov 27.